Azithromycin for Injection

Azithromycin for Injection (CAS 83905-01-5), available in 0.25g and 0.5g specifications, is indicated for first-line intravenous treatment of community-acquired pneumonia caused by pathogens such as Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus, or Streptococcus pneumoniae, as well as pelvic inflammatory disease caused by Chlamydia trachomatis, Neisseria gonorrhoeae, or Mycoplasma hominis. Manufactured in-house by CISEN PHARMACEUTICAL CO., LTD. to USP standards with samples available, it is distributed across North America, Europe, Australasia, Asia, the Middle East, and Africa.